[2025-10-23] HKSH Medical Group Announces World’s First Study on Multi-Target, Real-Time Stereotactic Total Ablative Radiotherapy with MR-LINAC for Oligometastatic Prostate Cancer Achieving 100% 3-Year Survival Rate without Severe Side Effects

CADLanceCheung 在 2025-10-23 提交

语言 Undefined

pdf:

category_en:

2025

慎防诈骗提示：近日接获有公众人士指称收到冒充养和医院的电话，并通知有医疗文件未领取，此类通讯均为冒充来电，切勿回覆或提供个人资料。公众人士请慎防冒充养和医疗集团或其成员包括养和医院、养和医健、养和东区医疗中心、养和癌症中心以及各关联公司名义的通讯 (虚假网站、电邮或语音来电等)。如有怀疑，切勿提供个人资料，并致电2572 0211与本集团联络。

山村园地

桌面版

语言

搜索表单

[2025-10-23] HKSH Medical Group Announces World’s First Study on Multi-Target, Real-Time Stereotactic Total Ablative Radiotherapy with MR-LINAC for Oligometastatic Prostate Cancer Achieving 100% 3-Year Survival Rate without Severe Side Effects